Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 in Advanced/Metastatic Urothelial Carcinoma
NCT01328574Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2011
- Primary completion
- May 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Mar 2011; status: completed.
02
Drugs
carotuximab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01328574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01328574.